查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024965

α放射性物質市場規模、佔有率、趨勢和預測：按放射性核種類型、醫療應用、最終用戶和地區分類，2026-2034年

Alpha Emitter Market Size, Share, Trends and Forecast by Type of Radionuclide, Medical Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2025年全球α粒子發射裝置市場規模為22.61億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到136.251億美元，2026年至2034年的複合年成長率（CAGR）為21.42%。目前，北美市場主導地位，預計2025年市佔率將超過43.7%。對標靶癌症治療的日益重視以及基於核醫學的新型產品核准數量的不斷成長，是推動α粒子發射裝置市場佔有率成長的主要因素。

癌症發生率的不斷上升以及對標靶α療法（TAT）這種先進治療方法的需求日益成長，正在推動全球α發射同位素市場的發展。錒-225和鐳-223等α發射同位素在精準腫瘤學中具有極高的應用價值，因為它們在提供高線性能量轉移率（LET）的同時，還能最大限度地減少對周圍健康組織的損傷。核子醫學的進步，以及政府和私營部門對放射性藥物研發投入的增加，正在加速該產業的成長。此外，α發射同位素在醫學影像和治療應用中的廣泛應用，以及創新放射性藥物獲得監管部門的核准，也推動了α發射同位素市場的需求。同位素製造技術的進步以及檢驗α發射療法對各種惡性腫瘤療效的臨床試驗數量的增加，也對市場產生了積極影響。

在美國，α粒子放射性藥物市場正迅速發展，其主要驅動力是癌症發病率的上升以及人們對靶向α粒子療法益處的認知不斷提高。例如，2020年全球報告新增癌症病例274,364例，凸顯了對更有效治療方法的迫切需求。對研發的大量投入推動了這一成長，並促進了放射性藥物和α粒子療法的進步。此外，美國市場受益於完善的醫療保健基礎設施和支持性法規，這些都有利於尖端治療方法的應用。監管機構產品核可數量不斷增加也促進了市場成長。

α粒子發射裝置市場的發展趨勢：

對標靶癌症療法的需求日益成長

人們對α放射性藥物的興趣日益濃厚，認為其能夠精準靶向癌細胞，同時最大限度減少對周圍健康組織的損傷，加之其應用領域的多元化，正在推動市場成長。此外，由於某些癌症對傳統藥物具有抗藥性，更有效的療法正在不斷研發，從而改善患者的預後。根據世界癌症研究基金會（WCRF）統計，2022年全球非皮膚癌（NMSC）病例總數總合19,976,499例。例如，2024年2月，美國食品藥物管理局（FDA）核准了由RadioMedix和Orano Med共同開發的標靶α療法AlphaMedix，並將其列為突破性醫療設備。此療法專注於治療神經內分泌腫瘤，展現了α放射性技術在更有效、更具標靶性的癌症治療方面的進步。

擴大α粒子發射材料生產能力

隨著α放射性藥物在癌症治療的應用日益廣泛，對大規模生產的需求也隨之成長。擴大生產基礎設施對於確保這些同位素的穩定供應，並滿足不斷成長的臨床和科學研究需求至關重要。例如，2024年1月，Orano Med在法國奧南啟動了一座新工廠的建設，該工廠專門用於生產鉛-212（Pb-212）放射性配體療法藥物。該工廠將提升大規模生產能力，進而提振α放射性藥物的市場前景。

製造技術的進步

由於更具擴充性和高效性的製造技術（例如基於迴旋加速器的生產技術）的發展，α粒子發射材料領域正在經歷一場變革。這些進步透過降低價格、提高同位素純度以及增強醫用級α粒子的可用性和可靠性，正在重振整個市場。例如，2024年3月，Actinium Pharmaceuticals啟動了一項策略項目，旨在利用其專有的迴旋加速器技術生產錒-225。該計畫旨在提供擴充性、經濟且具有卓越放射化學純度的技術，以滿足靶向癌症治療領域對α粒子發射材料日益成長的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球α粒子發射體市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場細分：依放射性核種類型分類

  • 砈
  • 鐳
  • 錕
  • 帶領
  • 鉍
  • 其他

第7章 市場區隔：依醫療用途分類

  • 攝護腺癌
  • 骨轉移
  • 卵巢癌
  • 胰臟癌
  • 內分泌腫瘤
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 醫學研究機構
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Actinium Pharmaceuticals, Inc.
    • Alpha Tau Medical Ltd.
    • Bayer Corporation
    • BWXT Medical Ltd
    • Fusion Pharma
    • IBA Radiopharma Solutions
    • NorthStar Medical Radioisotopes, LLC
    • Orano Group
    • RadioMedix, Inc.
    • Telix Pharmaceuticals Limited
    • TerraPower LLC
Product Code: SR112026A6398

The global alpha emitter market size was valued at USD 2,261.0 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 13,625.1 Million by 2034, exhibiting a CAGR of 21.42% from 2026-2034. North America currently dominates the market, holding a market share of over 43.7% in 2025. Factors such as the increasing focus on targeted cancer treatments, along with the rising number of new nuclear-medicine-based product approvals, are bolstering the alpha emitter market share.

The increased prevalence of cancer and the growing need for targeted alpha therapy (TAT) as an enhanced radiation treatment are driving the worldwide alpha emitter market forward. Alpha emitters, such as actinium-225 and radium-223, provide high linear energy transfer (LET) while causing minimum harm to nearby healthy tissues, making them excellent for precision oncology. Advances in nuclear medicine, together with increased government and private sector investment in radiopharmaceutical research, are accelerating industry growth. Furthermore, the growing use of alpha-emitting isotopes in medical imaging and therapeutic applications, together with regulatory approvals for innovative radiopharmaceuticals, is driving the alpha emitter market demand. The market also benefits from technological advances in isotope manufacturing and the increase of clinical trials testing alpha treatments for various malignancies.

The alpha emitter market in the United States is quickly developing, driven by rising cancer rates and greater awareness of the benefits of targeted alpha treatment. For example, in 2020, there were 274,364 new cancer cases worldwide, highlighting the growing need for improved therapies. Significant expenditures in R&D have fueled this rise, resulting in advancements in radiopharmaceuticals and alpha-emitting therapeutics. Furthermore, the United States market benefits from a robust healthcare infrastructure and supportive regulatory rules that stimulate the use of cutting-edge therapies. Furthermore, the increasing number of product approvals by regulatory bodies is providing an impetus to the market growth.

ALPHA EMITTER MARKET TRENDS:

Increasing Demand for Targeted Cancer Therapies

The expanding interest in alpha emitters as sources of targeting precisely cancerous cells with lesser destruction to surrounding normal tissue resulting in their diversified applications is impelling the market growth. It has also led to the development of more efficient drugs, mainly because some cancer diseases are unresponsive to drugs with conventional applications, thus giving the patient a better outcome. Cancer cases for NMSC reached a total of 19,976,499 worldwide in 2022 according to the World Cancer Research Fund. For example, in February 2024, the FDA granted a breakthrough device to AlphaMedix, a targeted alpha therapy developed by RadioMedix and Orano Med. This therapy is focused on treating neuroendocrine tumors, which shows advancements in alpha emitter technologies for more effective and targeted cancer treatments.

Expanding Production Capacity of Alpha Emitters

There is a growing need for larger-scale production as more applications for alpha emitters emerge in cancer treatment. Expanding manufacturing infrastructure is critical to ensure a steady supply of these isotopes, thereby meeting the increasing clinical and research demands. For instance, in January 2024, Orano Med began building a new site in Onnaing, France, dedicated to producing lead-212 radioligand therapies. This facility will enhance large-scale manufacturing capabilities. Therefore, supporting the alpha emitter market outlook.

Advancements in Manufacturing Technology

The alpha emitter sector is undergoing a revolution due to the development of more scalable and efficient manufacturing technologies, such as cyclotron-based production techniques. The market as a whole is improved by these developments as they lower prices, increase isotope purity, and make alpha particles for medical purposes more widely available and dependable. For example, Actinium Pharmaceuticals started a strategic project in March 2024 with the goal of manufacturing Actinium-225 using its in-house cyclotron-based technology. This advancement attempts to provide a scalable, economical technique with excellent radiochemical purity in order to meet the increasing need for alpha emitters in targeted cancer treatments.

ALPHA EMITTER INDUSTRY SEGMENTATION:

Analysis by Type of Radionuclide:

  • Astatine
  • Radium
  • Actinium
  • Lead
  • Bismuth
  • Others

Radium dominates the market with 54.5% shares in 2025. Radium, an alpha emitter, is commonly used in treating metastatic bone cancer. Its targeted approach delivers high-energy alpha particles to cancer cells, minimizing damage to healthy tissues. For example, Xofigo is a well-known treatment utilizing radium-223 for effective cancer management. The growing prevalence of bone metastases, particularly in prostate and breast cancer patients, is driving demand for radium-based therapies. Additionally, increased FDA approvals and ongoing research into expanding radium-223 applications beyond bone cancer are strengthening its market position. Pharmaceutical companies are also investing in optimizing radium formulations for improved efficacy and patient convenience. Moreover, strategic collaborations between healthcare providers and nuclear medicine manufacturers are enhancing accessibility to radium-based treatments, further fueling market growth. With continuous advancements in radiopharmaceutical development, radium's dominance in the alpha emitter market is expected to persist in the coming years.

Analysis by Medical Application:

  • Prostate Cancer
  • Bone Metastasis
  • Ovarian Cancer
  • Pancreatic Cancer
  • Endocrine Tumors
  • Others

With 36.0% market shares, bone metastasis dominates the alpha emitter industry, owing to the rising frequency of metastatic malignancies, notably prostate, breast, and lung cancer. Alpha-emitting radiopharmaceuticals, such as radium-223 (Xofigo), are commonly used to treat bone metastases because of their ability to precisely target cancer cells while causing minimal damage to adjacent tissues. The increasing need for less invasive, tailored therapy is driving market expansion. Furthermore, advances in nuclear medicine and increased FDA approvals of alpha-emitting medicines are broadening their clinical uses. Growing expenditures in R&D, together with increased patient knowledge and access to radiopharmaceuticals, are projected to maintain bone metastasis applications' dominance in the alpha emitter industry.

Analysis by End User:

  • Hospitals
  • Medical Research Institutions
  • Others

The global alpha emitter market is growing in hospitals due to rising cancer cases and the increasing adoption of targeted alpha therapy (TAT). Hospitals are incorporating alpha-emitting radiopharmaceuticals such as radium-223 and actinium-225 to enhance cancer treatment, leading to better patient outcomes and fewer side effects.

More investment in medical research institutions spurring alpha emitter application in advanced oncology and other therapeutic areas is driving also the growth of this market. Growing government and private funding support clinical trials, innovations in radiopharmaceuticals, and improved isotope production that accelerates new alpha-based treatments for diseases.

Other end users, including specialty clinics and nuclear medicine centers, contribute to market expansion by offering outpatient alpha therapy solutions. Growing collaborations between pharmaceutical companies and healthcare providers, along with improved regulatory frameworks, are further facilitating the widespread adoption of alpha emitters across diverse healthcare settings.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

As per the alpha emitter analysis report, North America leads the market with 43.7% shares due to strong investments in cancer therapies and advanced medical technologies. Apart from this, the region's focus on targeted alpha therapies for cancer treatment drives demand for alpha emitters like Actinium-225. For example, Actinium Pharmaceuticals in the U.S. is developing innovative alpha therapies for difficult-to-treat cancers. Furthermore, strong healthcare infrastructure and increasing research initiatives continue to propel market growth in North America, thereby ensuring the region remains a prominent player in the market. Additionally, the presence of key pharmaceutical companies, favorable regulatory policies, and increasing clinical trials for novel alpha-emitting radiopharmaceuticals further solidify North America's dominance in this rapidly expanding market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ALPHA EMITTER MARKET ANALYSIS

The U.S. alpha emitter market is expanding due to the rising incidence of chronic diseases and the increasing need for advanced treatment solutions. According to the U.S. Department of Health and Human Services, approximately 129 million Americans suffer from at least one major chronic condition, including heart disease, cancer, diabetes, obesity, or hypertension. This significant health burden fuels the need for more effective treatments, particularly in the field of cancer care. Alpha-emitting isotopes like actinium-225 and radium-223 are gaining attention for their potential in targeted cancer therapies, offering precision treatment options. The U.S. government's investments in cancer research and a favorable regulatory framework for radiopharmaceuticals further accelerate market growth. Additionally, the demand for diagnostic tools incorporating alpha emitters is on the rise, particularly in personalized medicine to identify and target cancerous tissues. The presence of key industry players and continuous innovation in radiopharmaceuticals strengthens the market's potential. With a growing aging population and rising cancer cases, along with increased funding from both public and private sectors, the U.S. alpha emitter market is poised for substantial growth in the coming years.

EUROPE ALPHA EMITTER MARKET ANALYSIS

The European alpha emitter market is expanding due to the rising incidence of cancer and the increasing demand for targeted treatment options. According to the analysis, the European Union's population on January 1, 2023, was predicted to be 448.8 million, with more than one-fifth (21.3%) aged 65 and more. This aging demographic, combined with rising cancer incidence, is greatly increasing the demand for effective cancer therapies. Alpha-emitting isotopes such as actinium-225, radium-223, and thorium-227 are gaining popularity for their capacity to administer precise, focused therapy, offering patients more effective treatment alternatives. Europe's favorable regulatory environment, with organizations such as the European Medicines Agency (EMA) favoring the approval of novel medicines, is boosting alpha emitter market growth. Furthermore, cooperation among academic institutions, pharmaceutical firms, and healthcare providers are increasing the use of alpha emitters. Europe's strong focus on research and development in radiopharmaceuticals is enabling continued advancements in cancer care, further boosting the market. The region's well-established healthcare system, along with increasing public and private sector funding, supports the expansion of alpha emitter usage. As these factors converge, Europe is projected to experience steady market expansion, especially in the field of cancer treatment, in the coming years.

ASIA PACIFIC ALPHA EMITTER MARKET ANALYSIS

The Asia Pacific (APAC) alpha emitter market is driven by rising cancer incidence, particularly ovarian cancer, which poses a significant burden in the region. According to reports, while developed countries face a higher risk of ovarian cancer, less developed nations, including China and India, report the highest number of diagnoses, with over 30,000 and 25,000 cases annually, respectively. India also has Asia's highest ovarian cancer mortality rate. This growing disease burden fuels demand for targeted alpha therapy (TAT), particularly for metastatic cancers. Increasing investments in nuclear medicine, advancements in isotope production such as actinium 225 and radium 223, and expanding healthcare infrastructure in China, Japan, and India support market growth. Governments and private entities are enhancing radiopharmaceutical supply chains and regulatory frameworks. Additionally, medical tourism in India and Thailand boosts demand for innovative cancer treatments. Strengthening research collaborations and rising government funding further accelerate the adoption of alpha emitting therapies in APAC.

LATIN AMERICA ALPHA EMITTER MARKET ANALYSIS

In Latin America, the alpha emitter market is gaining momentum due to the increasing prevalence of chronic diseases and a rising demand for advanced healthcare solutions. In Brazil, for instance, approximately 928,000 deaths are attributed to chronic diseases annually, according to reports. The increasing health burden is fueling demand for more effective treatment solutions, including radiopharmaceuticals that utilize alpha emitters. The adoption of precision medicine and advancements in cancer treatments are further boosting market potential. With government initiatives and international partnerships facilitating the development of radiopharmaceuticals, the alpha emitter market in Latin America is poised for growth.

MIDDLE EAST AND AFRICA ALPHA EMITTER MARKET ANALYSIS

The Middle East and Africa (MEA) alpha emitter market is driven by increasing adoption of targeted radionuclide therapies and expanding nuclear medicine infrastructure. Government initiatives to enhance oncology treatment and investments in healthcare facilities further support growth. According to PMC, Arab countries reported 463,675 new cancer cases, accounting for 2.4% of global incidence, highlighting the urgent need for advanced treatment options. Strategic collaborations between international radiopharmaceutical firms and regional providers improve accessibility. Growing awareness and clinical trials evaluating alpha-emitting radiopharmaceuticals fuel innovation.

COMPETITIVE LANDSCAPE:

The global alpha emitter market is highly competitive, with key players focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their market position. Major companies focus on advancing targeted alpha therapy (TAT) for cancer treatment. The market is driven by increasing investments in nuclear medicine and rising clinical research on radiopharmaceuticals. Regulatory approvals and government support for isotope production further shape the competitive landscape. Additionally, partnerships between pharmaceutical firms and research institutions are accelerating R&D efforts. Companies are also expanding their production capabilities to meet growing demand, especially in North America and Europe. However, stringent regulatory frameworks, limited isotope availability, and high production costs pose challenges.

The report provides a comprehensive analysis of the competitive landscape in the alpha emitter market with detailed profiles of all major companies, including:

  • Actinium Pharmaceuticals, Inc.
  • Alpha Tau Medical Ltd.
  • Bayer Corporation
  • BWXT Medical Ltd
  • Fusion Pharma
  • IBA Radiopharma Solutions
  • NorthStar Medical Radioisotopes, LLC
  • Orano Group
  • RadioMedix, Inc.
  • Telix Pharmaceuticals Limited
  • TerraPower LLC

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alpha Emitter Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type of Radionuclide

  • 6.1 Astatine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radium
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Actinium
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Lead
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Bismuth
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Medical Application

  • 7.1 Prostate Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Bone Metastasis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Ovarian Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pancreatic Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Endocrine Tumors
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Medical Research Institutions
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Actinium Pharmaceuticals, Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Alpha Tau Medical Ltd.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Bayer Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 BWXT Medical Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Fusion Pharma
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 IBA Radiopharma Solutions
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 NorthStar Medical Radioisotopes, LLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Orano Group
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 RadioMedix, Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Telix Pharmaceuticals Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 TerraPower LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Alpha Emitter Market: Major Drivers and Challenges
  • Figure 2: Global: Alpha Emitter Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Alpha Emitter Market: Breakup by Type of Radionuclide (in %), 2025
  • Figure 5: Global: Alpha Emitter Market: Breakup by Medical Application (in %), 2025
  • Figure 6: Global: Alpha Emitter Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Alpha Emitter Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Alpha Emitter (Astatine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Alpha Emitter (Astatine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Alpha Emitter (Radium) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Alpha Emitter (Radium) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Alpha Emitter (Actinium) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Alpha Emitter (Actinium) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Alpha Emitter (Lead) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Alpha Emitter (Lead) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Alpha Emitter (Bismuth) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Alpha Emitter (Bismuth) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Alpha Emitter (Other Type of Radionuclides) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Alpha Emitter (Other Type of Radionuclides) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Alpha Emitter (Prostate Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Alpha Emitter (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Alpha Emitter (Bone Metastasis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Alpha Emitter (Bone Metastasis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Alpha Emitter (Ovarian Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Alpha Emitter (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Alpha Emitter (Pancreatic Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Alpha Emitter (Pancreatic Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Alpha Emitter (Endocrine Tumors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Alpha Emitter (Endocrine Tumors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Alpha Emitter (Other Medical Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Alpha Emitter (Other Medical Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Alpha Emitter (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Alpha Emitter (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Alpha Emitter (Medical Research Institutions) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Alpha Emitter (Medical Research Institutions) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Alpha Emitter (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Alpha Emitter (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: North America: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: North America: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: United States: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: United States: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Canada: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Canada: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Asia-Pacific: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Asia-Pacific: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: China: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: China: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Japan: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Japan: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: India: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: India: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: South Korea: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: South Korea: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Australia: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Australia: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Indonesia: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Indonesia: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Others: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Others: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Europe: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Europe: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Germany: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Germany: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: France: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: France: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: United Kingdom: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: United Kingdom: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Italy: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Italy: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Spain: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Spain: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Russia: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Russia: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Others: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Others: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Latin America: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Latin America: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Brazil: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Brazil: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Mexico: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Mexico: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Others: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Others: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Middle East and Africa: Alpha Emitter Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Middle East and Africa: Alpha Emitter Market: Breakup by Country (in %), 2025
  • Figure 86: Middle East and Africa: Alpha Emitter Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Global: Alpha Emitter Industry: SWOT Analysis
  • Figure 88: Global: Alpha Emitter Industry: Value Chain Analysis
  • Figure 89: Global: Alpha Emitter Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alpha Emitter Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Alpha Emitter Market Forecast: Breakup by Type of Radionuclide (in Million USD), 2026-2034
  • Table 3: Global: Alpha Emitter Market Forecast: Breakup by Medical Application (in Million USD), 2026-2034
  • Table 4: Global: Alpha Emitter Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Alpha Emitter Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Alpha Emitter Market: Competitive Structure
  • Table 7: Global: Alpha Emitter Market: Key Players